Their is a poster on this board from time to time by the name of Letsgetrich. I consider him the most informative when he does post. He has stated before that he doesn't worry about dilution. I have the faith that the leadership group that Inmed has in place will lead this company to the promise land without diluting the stock.
My position isn't that there will be no dilution but that the dilution should be minimal and will not have a major impact on the pps. The higher the pps, the fewer shares that are required to fund the trials and other research. There are currently roughly 132 million shares outstanding (OS). They currently seem to have enough funding to carry them through the next 12 months by which time, if I'm right, we should be trading over $1/share. At $1/share it would take 10 million shares to raise $10 million. That would amount to roughly 7.5% dilution which, I would maintain, is a pretty manageable number for a growing company.
In addition, their past practice has been to sell thru private placements convertible securities, preferred shares or warrants that aren't immediately available for sale and/or counted in the OS. They currently have a shelf prospectus that allows them to sell up to $15 million in such securities during the next 25 months. You can check it out at the following link...
News 
Market Data 
Discover 
AI
